A Study of BGM0504 in Participants with Type 2 Diabetes

NCT06716216 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

537

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: Drug: 5 mg BGM0504 Administered SC
DRUG: Drug:10 mg BGM0504 Administered SC
DRUG: Drug: Semaglutide Administered SC

Sponsor

BrightGene Bio-Medical Technology Co., Ltd.

Collaborators

[object Object]